One hundred and twelve patients received hematopoictic stem cell transplantation (HSCT), including 91 patients with acute leukemia, 12 patients with chronic myeioid leukemia, 7 patients with lymphoma and 2 patients with myeloma and neuroblastoma respectively. Among them, 14 patients were treated with unpurged antologous bone marrow transplantation (ABMT), 25 patients with purged antologous bone marrow transplantation (PABMT), 40 patients with antologous peripheral blood hematopoietic stem cell transplantation (APBHSCT), 24 patients with allogeneic bone marrow transplantation (Ailo-BMT), 9 patients with fetal liver hematopoietic stem cell transplantation (FLHSCT). The three year disease free survival (DFS) rates in these five groups were 68.3%, 67.5%, 69.54%, 57.12% and 33.33% respectively. The relapse rates were 30.76%, 26.80%, 20.8%, 13% and 62.5% respectively. In contrast, in the conventional chemotherapy group, the three year DFS rate and relapse rate were 7.38% and 76.4% respectively. These results indicated that the APBHSCT group had a quicker hematopoietic reconstitation with less complication of infection. All of these five transplantation groups had much higher three years disease free survival rates' than that of the conventional chemotherapy group.